HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stemology Anti-Aging Line Leverages Stem Cells From Humans, Plants

This article was originally published in The Rose Sheet

Executive Summary

“Healing peptide” from adult human stem cells, plant stem cells and an intercellular communication enhancer make up the proprietary StemCore-3 technology in Dermatech Research’s Stemology skin-care line. Products in the collection range from $189 for Cell Revive Serum Complete to $19 for cleansing items.

You may also be interested in...



NuGene Growing Its Stem-Cell Cosmeceuticals Biz; Regulatory Risks Noted

NuGene's sales have soared with expanded distribution, but increased regulation continues to be a risk to its human stem-cell-based cosmeceuticals business, the firm notes. Skin and hair-care line extensions will launch later this year, and the company is considering developing an in-house sales force.

Lifeline Skin Care Grows Its Human Stem-Cell Anti-Aging Line

Lifeline Skin Care expands its offerings with an eye treatment featuring its patented stem-cell extract. Exec Linda Nelson explained International Stem Cell Corporation’s technology and its applications for Lifeline at the recent SupplySide West conference.

China Regulatory Probe Slows Nu Skin Growth After Record Year

The firm’s recent explosive growth is expected to slow substantially in the first quarter – to between 20% and 24% – but Nu Skin is confident the steps it is taking in China “make our long-term success more likely.” Analysts have faith in the firm as it works with Chinese officials to resolve an investigation into its business practices.

UsernamePublicRestriction

Register

RS018926

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel